Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides

International Journal of Cancer

Volumn 86, Issue 5, 2000, Pages 702-712

  Von Mensdorff Pouilly, Silvia ^a   Petrakou, Eftichia ^b   Kenemans, Peter ^a   Van Uffelen, Kees ^a   Verstraeten, Albert A ^a   Snijdewint, Frank G M ^a   Van Kamp, Gerard J ^a   Schol, Dick J ^a   Reis, Celso A ^d   Price, Michael R ^b   Livingston, Philip O ^c   Hilgers, Joseph ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Academic Hospital Free University ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPITOPE; GLYCOPEPTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; MUCIN; N ACETYLGALACTOSAMINE; PEPTIDE; QS 21; VACCINE;

ACTIVE IMMUNIZATION; ADENOCARCINOMA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TANDEM REPEAT; VACCINATION;

EID: 0034017653     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000601)86:5<702::aid-ijc16>3.0.co;2-1     Document Type: Article

References (35)

1. ADLURI, S., GILEWSKI, T., ZHANG, S., RAMNATH, V., RAGUPATHI, G. and LIVINGSTON, P., Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Brit. J. Cancer 79, 1806-1812 (1999).
2. BENNETT, E.P., HASSAN, H., MANDEL, U., MIRGORODSKAYA, E., ROEPSTORFF, P., BURCHELL, J., TAYLOR-PAPADIMITRIOU, J., HOLLINGSWORTH, M.A., MERKX, G., VANKESSEL, A.G., EIBERG, H., STEFFENSEN, R. and CLAUSEN, H., Cloning of a human UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. J. Biol. Chem. 273, 30472-30481 (1998).
3. BON, G.G., VON MENSDORFF-POUILLY, S., KENEMANS, P., VAN KAMP, G.J., VERSTRAETEN, R.A., HILGERS, J., MEIJER, S. and VERMORKEN, J.B., Clinical and technical evaluation of ACS™BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin. Chem. 43, 585-593 (1997).
4. BRIGGS, S., PRICE, M.R. and TENDLER, S.J.B., Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: Antibody binding to synthetic peptide epitopes. Eur. J. Cancer 29A, 230-237 (1993).
5. BURCHELL, J. and TAYLOR-PAPADIMITRIOU, J., Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epith. Cell Biol. 2, 155-162 (1993).
6. DOMENECH, N., HENDERSON, R.A. and FINN, O.J., Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155, 4766-4764 (1995).
7. FONTENOT, J.D., TJANDRA, N., BU, D., HO. C., MONTELARO, R.C. and FINN, O.J., Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res. 53, 5386-5394 (1993).
8. GENDLER, S.J., LANCASTER, C.A., TAYLOR-PAPADIMITRIOU, J., DUHIG, T., PEAT, N., BURCHELL, J., PEMBERTON, L., LALANI, E.-N. and WILSON, D., Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265, 15286-15293 (1990).
9. GILEWSKI, T., ADLURI, S., ZHANG, S., RAGUPATHI, G., HOUGHTON, A., NORTON, L. and LIVINGSTON, P.O., Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. (in press).
10. GOUREVITCH, M.M., VON MENSDORFF-POUILLY, S., LITVINOV, S.V., KENEMANS, P., VAN KAMP, G.J., VERSTRAETEN, A.A. and HILGERS, J., Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Brit. J. Cancer 72, 934-938 (1995).
11. HANISCH, F.G., MÜLLER, S., HASSAN, H., CLAUSEN, H., ZACHARA, N., GOOLEY, A.A., PAULSEN, H., ALVING, K. and PETER-KATALINIC, J., Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-acetylgalactosamine:peptide N-acetylgalactosaminyltransferases. J. Biol. Chem. 274, 9946-9954 (1999).
12. HENDERIKX, P., KANDILOGIANNAKI, M., PETRARCA, C., VON MENSDORFF-POUILLY, S., HILGERS, J.H.M., KRAMBOVITIS, E., ARENDS, J.W. and HOOGENBOOM, H.R., Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res. 58, 4324-4332 (1998).
13. HINODA, Y., NAKAGAWA, N., NAKAMURA, H., MAKIGUCHI, Y., ITOH, F., ADACHI, M., YABANA, T., IMAI, K. and YACHI, A., Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol. Lett. 35, 163-168 (1993).
14. KARANIKAS, V., HWANG, L.A., PEARSON, J., ONG, C.S., APOSTOLOPOULOS, V., VAUGHAN, H., XING, P.X., JAMIESON, G., PIETERSZ, G., TAIT, B., BROADBENT, R., THYNNE, G. and MCKENZIE, I.F.C., Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792 (1997).
15. KARSTEN, U., DIOTEL, C., KLICH, G., PAULSEN, H., GOLETZ, S., MÜLLER, S. and HANISCH, F.G., Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res. 58, 2541-2549 (1998).
16. KOTERA, Y., FONTENOT, J.D., PECHER, G., METZGAR, R.S. and FINN, O.J., Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54, 2856-2860 (1994).
17. LIVINGSTON, P.O., ZHANG, S. and LLOYD, K.O., Carbohydrate vaccines that induce antibodies against cancer. I. Rationale. Cancer Immunol. Immunother. 45, 1-9 (1997).
18. MACLEAN, G.D., REDDISH, M.A., KOGANTY, R.R. and LONGENECKER, B.M., Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. 19, 59-68 (1996).
19. MILES, D.W. and TAYLOR-PAPADIMITRIOU, J., Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma. Pharmacol. Ther. 82, 97-106 (1999).
20. MÜLLER, S., GOLETZ, S., PACKER, N., GOOLEY, A., LAWSON, A.M. and HANISCH, F.G., Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1 - All putative sites within the tandem repeat are glycosylation targets in vivo. J. Biol. Chem. 272, 24780-24793 (1997).
21. PETRAKOU, E., MURRAY, A. and PRICE, M.R., Epitope mapping of anti-MUC1 mucin protein core monoclonal antibodies. Tumor Biol. 19, 21-29 (1998).
22. PETRARCA, C., RUGHETTI, A., RAHIMI, H., DAGOSTINI, F., TURCHI, V., GHETTI, C.A., SCAMBIA, G., FRATI, L. and NUTI, M., Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region. Eur. J. Cancer 32A, 2155-2163 (1996).
23. PRICE, M. R. and 59 OTHERS, Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antbodies against the MUC1 mucin. Tumor Biol. 19(Supp 1), 1-20 (1998).
24. RICHARDS, E.R., DEVINE, P.L., QUIN, R.J., FONTENOT, J.D., WARD, B.G. and MCGUCKIN, M.A., Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 46, 245-252 (1998).
25. RUGHETTI, A., TURCHI, V., APOLLONJ-GHETTI, C., SCAMBIA, G., PANICI, P.B., RONCUCCI, G., MANCUSO, S., FRATI, L. and NUTI, M., Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 53, 2457-2459 (1993).
26. TAYLOR-PAPADIMITRIOU, J., BURCHELL, J., MILES, D.W., and DALZIEL, M., MUC1 and CANCER. Biochim Biophys Acta 1455, 301-313 (1999).
27. VAN DE WIEL-VAN KEMENADE, E., LIGHTENBERG, M.J.L., DE BOER, A.J., BUIJS, F., VOS, H.L., MELIEF, C.J.M., HILKENS, J. and FIGDOR, C.G., Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 151, 767-776 (1993).
28. VERHOEYEN, M.E., SAUNDERS, J.A., PRICE, M.R., MARUGG, J.D., BRIGGS, S., BRODERICK, E.L., EIDA, S.J., MOOREN, A.T. and BADLEY, R.A., Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. Immunology 78, 364-370 (1993).
29. VON MENSDORFF-POUILLY, S., GOUREVITCH, M.M., KENEMANS, P., VERSTRAETEN, A.A., LITVINOV, S.V., VAN KAMP, G.J., MEIJER, S., VERMORKEN, J. and HILGERS, J., Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur. J. Cancer 32A, 1325-1331 (1996).
30. VON MENSDORFF-POUILLY, S., GOUREVITCH, M.M., KENEMANS, P., VERSTRAETEN, A.A., VAN KAMP, G.J., KOK, A., VAN UFFELEN, K., SNIJDEWINT, F.G.M., PAUL, M.A., MEIJER, S. and HILGERS, J., An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol. 19, 186-195 (1998).
31. VON MENSDORFF-POUILLY, S., VERSTRAETEN, A.A., KENEMANS, P., SNIJDEWINT, F.G.M., KOK, A., VAN KAMP, G.J., PAUL, M.A., VAN DIEST, P.J., MEIJER, S. and HILGERS, J., Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin (MUC1). J. Clin. Oncol. 18, 574-583 (2000).
32. WANDALL, H.H., HASSAN, H., MIRGORODSKAYA, E., KRISTENSEN, A.K., ROEPSTORFF, P., BENNETT, E.P., NIELSEN, P.A., HOLLINGSWORTH, M.A., BURCHELL, J., TAYLOR-PAPADIMITRIOU, J. and CLAUSEN, H., Substrate specificities of three members of the human UDP-N-Acetyl-α-D-galactosamine:polypeptide N-Acetylgalactosaminyltransferase family, GalNac-T1, -T2, and -T3. J. Biol. Chem. 272, 23503-23514 (1997).
33. WESSELING, J., VAN DER VALK, S.W., VOS, H.L., SONNENBERG, A. and HILKENS, J., Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 129, 255-265 (1995).
34. WHITEHOUSE, C., BURCHELL, J., GSCHMEISSNER, S., BROCKHAUSEN, I., LLOYD, K.O. and TAYLOR-PAPADIMITRIOU, J., A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J. Cell Biol. 137, 1229-1241 (1997).
35. ZHANG, S., ZHANG, H.S., CORDON-CARDO, C., REUTER, V.E., SINGHAL, A.K., LLOYD, K.O. and LIVINGSTON, P.O., Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int. J. Cancer 73, 50-56 (1997).